Skip to main content
Premium Trial:

Request an Annual Quote

Syapse Closes $30M Series D Round

CHICAGO (GenomeWeb) – Syapse, a maker of software to support precision oncology care, has raised $30 million in a Series D round of venture capital from a variety of investors.

Previous investors that participated in the new round include Ascension Ventures, GE Ventures, Intermountain Healthcare Innovation Fund, Safeguard Scientifics, and Social Capital. Also investing this time are Amgen Ventures, Medidata Solutions, Merck Global Health Innovation Fund, and Roche Venture Fund.

San Francisco-based Syapse said it would use the cash infusion to step up sales and support for more hospitals, including community health systems. The company said this would help more eligible patients find and participate in relevant clinical trials.

"Targeted therapeutics and precision diagnostics have been shown to save lives and lower the cost of care, but without tools like Syapse, they've been inaccessible to the community oncologists that represent 70 percent of patient care," John Kuelper, investment director at Ascension Ventures, said in a statement. "Syapse empowers physicians to collaborate with each other and the broader medical ecosystem, ensuring that these breakthrough technologies are available to the patients who need them."

Syapse last announced a fundraise in early 2016, when it closed on a $25 million Series C round.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.